AngioSoma, Inc. Is Pleased To Welcome Robert Chicoski, CPA As Our New Chief Financial Officer and Treasurer
AngioSoma, Inc. (OTC PINK: SOAN) has appointed Robert Chicoski as its new Chief Financial Officer and Treasurer. Chicoski brings extensive financial expertise, including corporate finance and audit experience. The company, headquartered in Richland, Washington, is focused on innovating medical treatments, particularly in the field of wellness and diseases like Multiple Sclerosis. CEO James C. Katzaroff expressed confidence in Chicoski's ability to enhance the company’s financial operations. AngioSoma is committed to improving health through effective healthcare solutions.
- Appointment of experienced CFO Robert Chicoski to strengthen financial leadership.
- Focus on innovative medical treatments, particularly for Multiple Sclerosis.
- None.
Chicoski brings decades of robust financial experience to the AngioSoma management team
RICHLAND, WA / ACCESSWIRE / May 12, 2021 / AngioSoma, Inc. (OTC PINK:SOAN) has added Robert Chicoski as its Chief Financial Officer and Treasurer. Chicoski has decades of corporate financial, tax, audit and forensic accounting experience to the AngioSoma team.
Headquartered in Richland, Washington, AngioSoma, Inc. is a fast-growing company focused on providing medical research, development and treatments for wellness and disease. With a mission to "help people begin their journeys to improved health," AngioSoma brings innovative medical solutions to the market.
"The company is fortunate to onboard someone with Robert's experience and background in critical financial functions," said James C. Katzaroff, AngioSoma's CEO. "In this role, Robert will direct accounting, audit, tax and financial reporting, including all SEC reporting, auditing and budgeting, and he will generate analysis and commentary for the company."
In the 1990's, when two successful automobile salesmen decided to take advantage of the upcoming deregulation of electricity and natural gas, they hired Robert as CFO to write the business plan that would later raise their first million-dollar investment. As part of the management team, he facilitated the successful purchase of a million-dollar energy online reverse auction platform. As number three shareholder in Oceanside Energy Company, Robert helped secure the first major customer, the General Services Administration of the Federal government. Robert set the company up to go public as World Energy Solutions, Inc. (WEXCH). He later left the company to start a ministry for men coming out of prison.
In 2018, Robert became the U.S. representative for Fabrizio de Silvestri, the founder of the successful treatment for Multiple Sclerosis. In this role, he oversaw the progress to obtaining the U.S. patent.
"I have personally known people who have suffered Multiple Sclerosis and other chronic diseases," said Chicoski. "Working with a world-class team to bring a new form of treatment for diseases like Multiple Sclerosis, that I have personally seen work, is something exciting, challenging, and life-changing for everyone. I am excited to share my decades of financial experience with this team so we can move forward efficiently and effectively to help get our potential treatment to market."
NOTICE REGARDING FORWARD-LOOKING STATEMENTS
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words believes, expects, anticipate or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
About AngioSoma, Inc.
AngioSoma is a wellness company dedicated to bringing innovative, effective and high-quality healthcare solutions and medical devices to the market through our marketing subsidiary, SomaCeuticals™. AngioSoma is currently working in the field of Multiple Sclerosis, as well as other unsolved medical ailments, to find a way to enhance the quality of life for patients.
Learn more at www.angiosoma.com.
Notice Regarding Forward-Looking Statements
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words "believes," "expects," "anticipate" or similar expressions. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Media Contact:
Brooke Greenwald
Cornerstone Communications, LTD
brooke@cornerstonepr.net
240-360-0866
SOURCE: AngioSoma, Inc.
View source version on accesswire.com:
https://www.accesswire.com/646665/AngioSoma-Inc-Is-Pleased-To-Welcome-Robert-Chicoski-CPA-As-Our-New-Chief-Financial-Officer-and-Treasurer
FAQ
Who is the new CFO of AngioSoma?
What is AngioSoma's focus area?
What stock symbol does AngioSoma operate under?
What experience does Robert Chicoski bring to AngioSoma?
What is the mission of AngioSoma?
